COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,794 Articles (22,527 medRxiv, 8,267 bioRxiv)

Most recent first Previous |  Page 683: Articles 6821-6830  | Next

The Functional Landscape of SARS-CoV-2 3CL Protease
Iketani, S., Hong, S. J., Sheng, J., Bahari, F., Culbertson, B., Atanaki, F. F., Aditham, A. K., Kratz, A. F., Luck, M. I., Tian, R., Goff, S. P., Montazeri, H., Sabo, Y., Ho, D. D., Chavez, A.
10.1101/2022.06.23.497404 — Posted: 2022-06-24
Monitoring SARS-CoV-2 infection using a double reporter-expressing virus
Chiem, K., Park, J.-G., Morales Vasquez, D., Plemper, R. K., Torrelles, J. B., Kobie, J., Walter, M. R., Ye, C., Martinez-Sobrido, L.
10.1101/2022.06.23.497376 — Posted: 2022-06-24
Association of physical activity and the risk of COVID-19 hospitalization: a dose-response meta-analysis
Li, D., Jin, S., Lu, S.
10.1101/2022.06.22.22276789 — Posted: 2022-06-23
On the impacts of the COVID-19 pandemic on mortality: Lost years or lost days?
Rousson, V., Locatelli, I.
10.1101/2022.06.23.22276812 — Posted: 2022-06-23
Hill numbers at the edge of a pandemic: rapid SARS-COV2 surveillance without alignments or trees
Narechania, A., Bobo, D., Deitz, K., DeSalle, R., Planet, P., Mathema, B.
10.1101/2022.06.23.22276807 — Posted: 2022-06-23
Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalisation: a systematic review and meta-analysis.
Meggiolaro, A., Sane Schepisi, M., Farina, S., Castagna, C., Mammone, A., Siddu, A., Stefanelli, P., Boccia, S., Rezza, G.
10.1101/2022.06.23.22276809 — Posted: 2022-06-23
In vivo virological efficacy of monoclonal antibodies and direct antiviral agents against the SARS-CoV-2 BA.1 and BA.2 Omicron sublineages
Mazzotta, V., Cozzi Lepri, a., Colavita, F., Rosati, S., Lalle, E., Cimaglia, C., Paulicelli, J., Mastrorosa, I., Vergori, A., Girardi, E., Garburglia, A. R., Vaia, F., Nicastri, E., Antinori, A.
10.1101/2022.06.23.22276509 — Posted: 2022-06-23
SARS-CoV-2 breakthrough infection during the Delta-dominant epidemic and neutralizing antibodies against Omicron in comparison with the third dose of BNT162b2: a matched analysis
Yamamoto, S., Matsuda, K., Maeda, K., Oshiro, Y., Inamura, N., Mizoue, T., Konishi, M., TAKEUCHI, J. S., Horii, K., Ozeki, M., Sugiyama, H., Mitsuya, H., Sugiura, W., Ohmagari, N.
10.1101/2022.06.21.22276682 — Posted: 2022-06-23
OpenSAFELY: Representativeness of Electronic Health Record platform OpenSAFELY-TPP data compared to the population of England.
The OpenSAFELY Collaborative, , Andrews, C. D., Schultze, A., Curtis, H. J., Hulme, W. J., Tazare, J., Evans, S. J., Mehrkar, A., Bacon, S. C., Hickman, G., Bates, C., Parry, J., Hester, F., Harper, S., Cockburn, J., Evans, D., Ward, T., Davy, S., Inglesby, P., Goldacre, B., MacKenna, B., Tomlinson, L. A., Walker, A. J.
10.1101/2022.06.23.22276802 — Posted: 2022-06-23
S373P Mutation of Spike Protein in SARS-CoV-2 Stabilizes Omicron
Zheng, B., Xiao, Y., Tong, B., Mao, Y., Ge, R., Tian, F., Dong, X., Zheng, P.
10.1101/2022.06.22.497114 — Posted: 2022-06-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).